Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2010
05/18/2010CA2284041C Indolecarboxamides, pharmaceutical compositions and methods of inhibiting calpain
05/18/2010CA2259143C G-beta-gamma regulated phosphatidylinositol-3' kinase p101 regulatory subunit
05/18/2010CA2216717C Compositions for the diagnosis, prevention, and treatment of tumor progression
05/18/2010CA2131797C Condensed indole derivatives as 5ht4-receptor antagonists
05/14/2010WO2010054405A1 Novel lipids and compositions for the delivery of therapeutics
05/14/2010WO2010054401A1 Novel lipids and compositions for the delivery of therapeutics
05/14/2010WO2010054398A1 Compounds useful as inhibitors of atr kinase
05/14/2010WO2010054384A1 Lipids and compositions for the delivery of therapeutics
05/14/2010WO2010054381A2 Method of treating cancer with a combination of a proteasome inhibitor and salubrinal
05/14/2010WO2010054356A1 Pharmaceutical formulations for iontophoretic delivery of a corticosteroid
05/14/2010WO2010054344A1 Anti-inflammatory compounds and compositions thereof
05/14/2010WO2010054336A2 Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction
05/14/2010WO2010054331A1 Microrna-mediated regulation of ubc9 expression in cancer cells
05/14/2010WO2010054307A1 Compounds and methods of promoting oligodendrocyte precursor differentiation
05/14/2010WO2010054294A1 Pirfenidone treatment for patients with atypical liver function
05/14/2010WO2010054286A2 Substituted hydroxyphenylamine compounds
05/14/2010WO2010054285A2 Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
05/14/2010WO2010054279A1 Compounds for the treatment of inflammatory disorders
05/14/2010WO2010054278A2 Compounds for the treatment of inflammatory disorders
05/14/2010WO2010054267A1 Immunosuppression compound and treatment method
05/14/2010WO2010054264A1 Use of catecholic butane derivatives in cancer therapy
05/14/2010WO2010054260A1 Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases
05/14/2010WO2010054253A1 Triazine derivatives as inhibitors of phosphodiesterases
05/14/2010WO2010054248A1 Trans-clomiphene for metabolic syndrome and diabetes mellitus type 2
05/14/2010WO2010054229A1 Quinoxaline-based lxr modulators
05/14/2010WO2010054223A1 Lysosomotropic inhibitors of acid ceramidase
05/14/2010WO2010054189A1 Role of soluble upar in the pathogenesis of proteinuric kidney disease
05/14/2010WO2010054158A2 Steroid modulators of glucocorticoid receptor
05/14/2010WO2010054135A1 Low dose lipoic acid pharmaceutical compositions and methods
05/14/2010WO2010054126A2 Small molecule modulators of epigenetic regulation and their therapeutic applications
05/14/2010WO2010054125A1 Formulations and uses of 24r, 25-dihydroxyvitamin d3 as an anti-apoptotic
05/14/2010WO2010054114A2 Cycloalkane[b]azaindole antagonists of prostaglandin d2 receptors
05/14/2010WO2010054113A2 Cycloalkane[b]azaindole antagonists of prostaglandin d2 receptors
05/14/2010WO2010054107A2 Kinase knockdown via electrophilically enhanced inhibitors
05/14/2010WO2010054093A1 Formulations for the treatment of acute herpes zoster pain
05/14/2010WO2010054078A1 Gamma secretase modulators
05/14/2010WO2010054068A2 Cyclic adenosine monophosphates for reducing the formation of adhesions
05/14/2010WO2010054067A1 Gamma secretase modulators
05/14/2010WO2010054064A1 Gamma secretase modulators
05/14/2010WO2010054058A1 Imidazolothiazole compounds as modulators of protein kinase
05/14/2010WO2010054056A2 Nilotinib hci crystalline forms
05/14/2010WO2010054052A1 Compositions and methods of sirt activation
05/14/2010WO2010054051A1 Erbb-3 (her3)-selective combination therapy
05/14/2010WO2010054042A2 Dimethylphenoxy modulators of viral protease activity and/or parasitic enzyme activity
05/14/2010WO2010054024A2 Novel compounds as cannabinoid receptor ligands
05/14/2010WO2010054020A1 [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
05/14/2010WO2010054015A2 Methods of reducing the risk of cardiovascular disease in postmenopausal women
05/14/2010WO2010054009A1 Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions
05/14/2010WO2010054006A1 Modulators of cxcr7
05/14/2010WO2010054003A2 Methylindazole modulators of 5-ht3 receptors
05/14/2010WO2010054001A2 D-tagatose-based compositions and methods for preventing and treating atherosclerosis, metabolic syndrome, and symptoms thereof
05/14/2010WO2010053998A1 Spiro-condensed indole derivatives as sodium channel inhibitors
05/14/2010WO2010053975A1 Modulation of toll-like receptor 4 expression by antisense oligonucleotides
05/14/2010WO2010053974A2 Stable organic peroxide compositons
05/14/2010WO2010053942A1 Methods for treating hepatitis c virus infection
05/14/2010WO2010053918A1 Composite containing collagen and elastin as a dermal expander and tissue filler
05/14/2010WO2010053902A2 Tryptase enzyme inhibiting aminothiophenols
05/14/2010WO2010053861A2 Biologically active amides
05/14/2010WO2010053854A1 Medication and treatment for disease
05/14/2010WO2010053835A1 Compositions and methods for minimizing or reversing agonist-induced desensitization
05/14/2010WO2010053829A1 Soluble epoxide hydrolase inhibitors for treatment of metabolic syndrome and related disorders
05/14/2010WO2010053825A1 2-aminopyrimidine compounds as serotonin receptor modulators
05/14/2010WO2010053817A1 Betulinic acid derivatives and methods of use thereof
05/14/2010WO2010053757A1 2 -oxoquinoxalin blockers of the late sodium channel
05/14/2010WO2010053732A1 Isoindoline compounds for use in the treatment of cancer
05/14/2010WO2010053691A1 Immediate release dosage forms of sodium oxybate
05/14/2010WO2010053655A2 Therapeutic methods with withaferin a and analogs
05/14/2010WO2010053606A2 Small-molecule inhibitors of protein synthesis inactivating toxins
05/14/2010WO2010053583A2 Small molecule cd4 mimetics and uses thereof
05/14/2010WO2010053517A2 Combination therapy to combat helminth resistance
05/14/2010WO2010053487A1 Composition containing sulfoalkyl ether cyclodextrin and latanoprost
05/14/2010WO2010053471A1 Modulators of atp-binding cassette transporters
05/14/2010WO2010053455A1 Novel polyamino polyketide antibiotics and uses thereof
05/14/2010WO2010053438A1 Modulators of amyloid beta.
05/14/2010WO2010053435A2 Compounds and methods for the treatment of inflammatory diseases of the cns
05/14/2010WO2010053433A1 Increased expression of specific antigens
05/14/2010WO2010053430A1 Compounds and methods for reducing the recruitment and/or migration of polymorphonuclear cells
05/14/2010WO2010053388A1 New 4,6-disubstituted 2-(4-methylpiperazin-1-yl)pyridine derivatives, a process for their preparation, pharmaceutical composition containing these compounds, their use, a method for modulating monoaminergic receptor activity and a monoaminergic receptor modulating agent
05/14/2010WO2010053343A1 Process for obtaining a composition of rosuvastatin calcium and product obtained
05/14/2010WO2010053316A2 New use of sixth immunoglobulin-like domain of vcam-1
05/14/2010WO2010053306A2 Pharmaceutical composition for the controlled release of methylphenidate
05/14/2010WO2010053218A1 Fluorinated benzothiazole derivatives, preparation method thereof and imaging agent for diagnosing altzheimer's disease using the same
05/14/2010WO2010053182A1 Kynurenine production inhibitor
05/14/2010WO2010053165A1 Vitamin d3 lactam derivative
05/14/2010WO2010053127A1 MODULATOR OF α1GABAA RECEPTOR OR α5GABAA RECEPTOR
05/14/2010WO2010053120A1 Carbamate compound or salt thereof
05/14/2010WO2010053085A1 Agent for preventing acidosis in ruminant animals
05/14/2010WO2010053068A1 Novel useful therapeutic agent for lower urinary tract symptom
05/14/2010WO2010052993A1 Anthracene derivative cycloadded with acylnitroso derivative, and light-activated hno donor
05/14/2010WO2010052896A1 Preparation for local administration containing fluticasone propionate
05/14/2010WO2010052873A1 Dihydrochloride of indazole derivative
05/14/2010WO2010052847A1 Concentrated liquid diet
05/14/2010WO2010052836A1 Aqueous solution of antimicrobial agent and method for producing same
05/14/2010WO2010052734A1 Substituted benzfurochromenes and related compounds for the prevention and treatment of bone related disorders
05/14/2010WO2010052733A1 NOVEL 4β-AMINO PODOPHVLLOTOXIN CONGENERS AS ANTI TUMOUR ANTIBIOTICS A PROCESS FOR THE PREPARATION THEREOF
05/14/2010WO2010052732A1 Cinnamido-pvrrolor[2,1-c][1,4]benzodiazepines as potential anticancer agents and process for the preparation thereof
05/14/2010WO2010052670A1 PROCESS TO PREPARE NEW SUBSTITUTED 1H-BENZO [d] IMIDAZOL-2(3H)-ONES, NEW INTERMEDIATES AND THEIR USE AS BACE 1 INHIBITORS
05/14/2010WO2010052625A1 Pyrrolidines
05/14/2010WO2010052575A2 Ngna compositions and methods of use
05/14/2010WO2010052508A1 Ligands of vitamin d nuclear receptors with cell maturation promotion factors
1 ... 2266 2267 2268 2269 2270 2271 2272 2273 2274 2275 2276 2277 2278 2279 2280 2281 2282 2283 2284 2285 2286 ... 7860